Business
BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences
Scientific findings will discuss circulating tumor cells as a biomarker of tumor respons...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell's BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment. Phase I/IIa clinical efficacy data will be announced in advance of these conferences. NEW YORK, NY / ACCESSWIRE / September 21, 2018 / BriaCell Therapeutics Corp. (TSX-V: BCT) (OTCQB: BCTXF) (\"BriaCell\"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today it will present the data from biomarker analyses of its clinical trials for advanced breast cancer at the Fourth International Cancer Immunotherapy Conference as well as at The MicroCap Conference, both of which will take place in New York City.The details of the conferences are as follows:Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (Sept. 30 – Oct. 3, 2018, New York, NY, USA)Abstract Title: SV-BR-1-GM, a whole-cell targeted immunotherapy for advanced breast cancer: Pharmacodynamic markers of responseAbstract/Poster Number: A012Date: Sunday, Sept. 30Time: 11:45 a.m.-2:15 p.m.Location: New York Marriott Marquis, Westside BallroomThe poster to be presented by BriaCell will describe recent findings related to biological (pharmacodynamic) and clinical responses to treatment with Bria-IMT™ in advanced breast cancer patients enrolled in the Company's ongoing Phase I/IIa Study of Bria-IMT™ in metastatic or locally recurrent breast cancer patients, listed in ClinicalTrials.gov as NCT03066947. Among others, potential correlations between circulating tumor-associated cells obtained from liquid biopsies and tumor response will be discussed. These findings are key to the advancement of BriaCell's BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment.Following the presentation, copies of the abstract and the poster will be posted on http://briacell.com/investor-relations/presentations/. \"Among other findings, we have seen that certain changes in the number of large tumor-associated cells we found in the blood of breast cance...